Short Interest in Innovent Biologics, Inc. (OTCMKTS:IVBXF) Declines By 68.5%

Innovent Biologics, Inc. (OTCMKTS:IVBXF) saw a large decrease in short interest during the month of March. As of March 13th, there was short interest totaling 353,427 shares, a decrease of 68.5% from the February 26th total of 1,121,342 shares. Based on an average trading volume of 2,134 shares, the days-to-cover ratio is currently 165.6 days. Based on an average trading volume of 2,134 shares, the days-to-cover ratio is currently 165.6 days.

Innovent Biologics Stock Performance

IVBXF stock remained flat at $9.75 during midday trading on Wednesday. The company’s stock had a trading volume of 4,400 shares, compared to its average volume of 1,963. Innovent Biologics has a 52-week low of $5.00 and a 52-week high of $15.12. The stock’s 50 day moving average is $10.68 and its two-hundred day moving average is $11.22.

About Innovent Biologics

Innovent Biologics is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of high-quality biologic therapies. Founded in 2011 and headquartered in the Suzhou National Biotech R&D Park, the company specializes in innovative treatments across oncology, metabolic and ophthalmology indications. Innovent’s integrated model encompasses end-to-end capabilities, from early discovery and clinical development to large-scale manufacturing and market launch.

The company has built a diversified product portfolio that includes the anti-PD-1 monoclonal antibody sintilimab (Tyvyt), approved for lymphoma and non-small cell lung cancer in China, as well as multiple biosimilars such as IBI305 (a bevacizumab biosimilar) and IBI306 (an etanercept biosimilar).